ArticleJournal of translational medicine2025
Dissolving microneedles enabled delivery of Oxaliplatin- sodium butyrate loaded outer membrane vesicles against rectal cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOxaliplatin (OXA) is a commonly used drug for the treatment of rectal cancer (RC). However, traditional administration methods are plagued by low efficiency, high systemic side effects, and poor patient tolerance. Therefore, there is an urgent need to develop a targeted drug delivery system to enhance efficacy and reduce toxicity.
methodsA strain of Clostridium butyricum with anti-cancer properties was screened, and outer membrane vesicles (OMVs) rich in sodium butyrate (NaB) were prepared. These OMVs (NaB-OMVs, NOMVs) were used to address the challenge of combined administration caused by differences in the administration methods and physicochemical properties of OXA and NaB. OXA was encapsulated into NOMVs via sonication to obtain OXA-loaded NaB-OMVs (OXA@NOMVs, ONOMVs). To improve stability and enable targeted delivery, a dissolving microneedle (MNs) system (ONOMVs@MNs) was developed using PVP K90 and sodium hyaluronate via the mold method. The system was characterized for morphology, size, zeta potential, mechanical strength, and rectal mucosa permeability. Additionally, targeted therapy advantages were evaluated using methods including anal microneedle administration in mice and fluorescence labeling of vesicles.
resultsCharacterization showed that ONOMVs exhibit a saucer-like morphology with a diameter of 100 nm and a zeta potential of 20 mV. The ONOMVs@MNs were conically shaped and possessed sufficient mechanical strength to penetrate the anal mucosa. In rectal mucosa permeability experiments, the 2-hour permeability of the MNs group was 1.78 times higher than that of the liquid (liquor) group. Anal microneedle administration in mice and fluorescence labeling confirmed the targeted therapy advantages of NOMVs@MNs.
conclusionsONOMVs@MNs is an efficient local drug delivery platform that combines NaB and OXA, providing a potential therapeutic approach for RC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.